Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer

Cellular Immunology

Volumn 294, Issue 1, 2015, Pages 54-59

  Zheng, Yawen ^a   Dou, Yan ^a   Duan, Lili ^a   Cong, Changsheng ^a   Gao, Aiqin ^a   Lai, Qinghua ^a   Sun, Yuping ^a  

^a JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Chemo drug; Immune tolerance; Immunotherapy; Irradiation; Low dose

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; GEMCITABINE; PACLITAXEL; ALKYLATING AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL MATURATION; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LOW DRUG DOSE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; WHOLE BODY RADIATION; ANALOGS AND DERIVATIVES; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; NATURAL KILLER CELL; NEOPLASMS; PROCEDURES; RADIATION RESPONSE; TUMOR ESCAPE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; PACLITAXEL; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84923056991     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.02.003     Document Type: Review

References (77)

1. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29:235-271.
2. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
3. Kirkwood J.M., Butterfield L.H., Tarhini A.A., Zarour H., Kalinski P., Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J. Clin. 2012, 62:309-335.
4. Robert C., Thomas L., Bondarenko I., O'Day S., Jeffrey Weber M.D., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., Davidson N., Richards J., Maio M., Hauschild A., Miller W.J., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T.T., Humphrey R., Hoos A., Wolchok J.D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
5. Taneja S.S. Re: safety, activity, and immune correlates of anti-PD-1 antibody in cancer. J. Urol. 2012, 188:2149.
6. Ruiz R., Hunis B., Raez L.E. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines. Curr. Oncol. Rep. 2014, 16:400.
7. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 2012, 12:269-281.
8. Tang S., Lotze M.T. The power of negative thinking: which cells limit tumor immunity?. Clin. Cancer Res. 2012, 18:5157-5159.
9. Kershaw M.H., Devaud C., John L.B., Westwood J.A., Darcy P.K. Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology 2013, 2:e25962.
10. Yu X., Zhao H., Liu L., Cao S., Ren B., Zhang N., An X., Yu J., Li H., Ren X. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J. Clin. Immunol. 2014, 34:194-203.
11. Kalathil S., Lugade A.A., Miller A., Iyer R., Thanavala Y. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013, 73:2435-2444.
12. Yao X., Ahmadzadeh M., Lu Y.C., Liewehr D.J., Dudley M.E., Liu F., Schrump D.S., Steinberg S.M., Rosenberg S.A., Robbins P.F. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012, 119:5688-5696.
13. Li H., Yu J.P., Cao S., Wei F., Zhang P., An X.M., Huang Z.T., Ren X.B. CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J. Clin. Immunol. 2007, 27:317-326.
14. Hinrichs C.S., Rosenberg S.A. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol. Rev. 2014, 257:56-71.
15. Bayne L.J., Beatty G.L., Jhala N., Clark C.E., Rhim A.D., Stanger B.Z., Vonderheide R.H. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012, 21:822-835.
16. Arina A. Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer. Oncoimmunology 2014, 3:e28464.
17. Tang X., Mo C., Wang Y., Wei D., Xiao H. Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 2013, 138:93-104.
18. Mano Y., Aishima S., Fujita N., Tanaka Y., Kubo Y., Motomura T., Taketomi A., Shirabe K., Maehara Y., Oda Y. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. Pathobiology 2013, 80:146-154.
19. Mok S., Koya R.C., Tsui C., Xu J., Robert L., Wu L., Graeber T.G., West B.L., Bollag G., Ribas A. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014, 74:153-161.
20. Chan C.Y., St J.A., Abraham S.N. Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 2013, 38:349-359.
21. Zhang L., Feng D., Yu L.X., Tsung K., Norton J.A. Preexisting antitumor immunity augments the antitumor effects of chemotherapy. Cancer Immunol. Immunother. 2013, 62:1061-1071.
22. McCoy M.J., Lake R.A., van der Most R.G., Dick I.M., Nowak A.K. Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. Br. J. Cancer 2012, 107:1107-1115.
23. Shurin G.V., Tourkova I.L., Kaneno R., Shurin M.R. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J. Immunol. 2009, 183:137-144.
24. Ding Z.C., Lu X., Yu M., Lemos H., Huang L., Chandler P., Liu K., Walters M., Krasinski A., Mack M., Blazar B.R., Mellor A.L., Munn D.H., Zhou G. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer Res. 2014, 74:3441-3453.
25. Le D.T., Jaffee E.M. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012, 72:3439-3444.
26. Wada S., Yoshimura K., Hipkiss E.L., Harris T.J., Yen H.R., Goldberg M.V., Grosso J.F., Getnet D., Demarzo A.M., Netto G.J., Anders R., Pardoll D.M., Drake C.G. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 2009, 69:4309-4318.
27. Brode S., Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit. Rev. Immunol. 2008, 28:109-126.
28. Ghiringhelli F., Menard C., Puig P.E., Ladoire S., Roux S., Martin F., Solary E., Le Cesne A., Zitvogel L., Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56:641-648.
29. Motoyoshi Y., Kaminoda K., Saitoh O., Hamasaki K., Nakao K., Ishii N., Nagayama Y., Eguchi K. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol. Rep. 2006, 16:141-146.
30. Rozados V.R., Mainetti L.E., Rico M.J., Zacarias F.M., Matar P., Scharovsky O.G. The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. Oncol. Res. 2010, 18:601-605.
31. Sevko A., Sade-Feldman M., Kanterman J., Michels T., Falk C.S., Umansky L., Ramacher M., Kato M., Schadendorf D., Baniyash M., Umansky V. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J. Invest. Dermatol. 2013, 133:1610-1619.
32. Le H.K., Graham L., Cha E., Morales J.K., Manjili M.H., Bear H.D. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 2009, 9:900-909.
33. Alizadeh D., Trad M., Hanke N.T., Larmonier C.B., Janikashvili N., Bonnotte B., Katsanis E., Larmonier N. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014, 74:104-118.
34. Javeed A., Ashraf M., Riaz A., Ghafoor A., Afzal S., Mukhtar M.M. Paclitaxel and immune system. Eur. J. Pharm. Sci. 2009, 38:283-290.
35. Umansky V., Sevko A. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol. Immunother. 2012, 61:275-282.
36. Sevko A., Michels T., Vrohlings M., Umansky L., Beckhove P., Kato M., Shurin G.V., Shurin M.R., Umansky V. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 2013, 190:2464-2471.
37. Vicari A.P., Luu R., Zhang N., Patel S., Makinen S.R., Hanson D.C., Weeratna R.D., Krieg A.M. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol. Immunother. 2009, 58:615-628.
38. Pfannenstiel L.W., Lam S.S., Emens L.A., Jaffee E.M., Armstrong T.D. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell. Immunol. 2010, 263:79-87.
39. Zhong H., Han B., Tourkova I.L., Lokshin A., Rosenbloom A., Shurin M.R., Shurin G.V. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin. Cancer Res. 2007, 13:5455-5462.
40. Ko H.J., Kim Y.J., Kim Y.S., Chang W.S., Ko S.Y., Chang S.Y., Sakaguchi S., Kang C.Y. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007, 67:7477-7486.
41. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11:6713-6721.
42. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., Martin F., Apetoh L., Rebe C., Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010, 70:3052-3061.
43. Tongu M., Harashima N., Monma H., Inao T., Yamada T., Kawauchi H., Harada M. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol. Immunother. 2013, 62:383-391.
44. Shevchenko I., Karakhanova S., Soltek S., Link J., Bayry J., Werner J., Umansky V., Bazhin A.V. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int. J. Cancer 2013, 133:98-107.
45. Ugel S., Peranzoni E., Desantis G., Chioda M., Walter S., Weinschenk T., Ochando J.C., Cabrelle A., Mandruzzato S., Bronte V. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2012, 2:628-639.
46. Formenti S.C., Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009, 10:718-726.
47. Lorimore S.A., Coates P.J., Scobie G.E., Milne G., Wright E.G. Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects?. Oncogene 2001, 20:7085-7095.
48. Lorimore S.A., Chrystal J.A., Robinson J.I., Coates P.J., Wright E.G. Chromosomal instability in unirradiated hemaopoietic cells induced by macrophages exposed in vivo to ionizing radiation. Cancer Res. 2008, 68:8122-8126.
49. Formenti S.C., Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl. Cancer Inst. 2013, 105:256-265.
50. Draghiciu O., Walczak M., Hoogeboom B.N., Franken K.L., Melief K.J., Nijman H.W., Daemen T. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int. J. Cancer 2014, 134:859-872.
51. Lugade A.A., Moran J.P., Gerber S.A., Rose R.C., Frelinger J.G., Lord E.M. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 2005, 174:7516-7523.
52. Yang G., Kong Q., Wang G., Jin H., Zhou L., Yu D., Niu C., Han W., Li W., Cui J. Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother. Radiopharm. 2014, 29:428-434.
53. Matsumura S., Wang B., Kawashima N., Braunstein S., Badura M., Cameron T.O., Babb J.S., Schneider R.J., Formenti S.C., Dustin M.L., Demaria S. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 2008, 181:3099-3107.
54. Levy A., Chargari C., Cheminant M., Simon N., Bourgier C., Deutsch E. Radiation therapy and immunotherapy: implications for a combined cancer treatment. Crit. Rev. Oncol. Hematol. 2013, 85:278-287.
55. Teitz-Tennenbaum S., Li Q., Davis M.A., Wilder-Romans K., Hoff J., Li M., Chang A.E. Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J. Immunother. 2009, 32:602-612.
56. Moyer J.S., Li J., Wei S., Teitz-Tennenbaum S., Chang A.E. Intratumoral dendritic cells and chemoradiation for the treatment of murine squamous cell carcinoma. J. Immunother. 2008, 31:885-895.
57. Newcomb E.W., Demaria S., Lukyanov Y., Shao Y., Schnee T., Kawashima N., Lan L., Dewyngaert J.K., Zagzag D., McBride W.H., Formenti S.C. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin. Cancer Res. 2006, 12:4730-4737.
58. Demaria S., Kawashima N., Yang A.M., Devitt M.L., Babb J.S., Allison J.P., Formenti S.C. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 2005, 11:728-734.
59. Wrzesinski C., Paulos C.M., Kaiser A., Muranski P., Palmer D.C., Gattinoni L., Yu Z., Rosenberg S.A., Restifo N.P. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 2010, 33:1-7.
60. Powell D.J., Dudley M.E., Hogan K.A., Wunderlich J.R., Rosenberg S.A. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J. Immunol. 2006, 177:6527-6539.
61. Chang C.L., Hsu Y.T., Wu C.C., Lai Y.Z., Wang C., Yang Y.C., Wu T.C., Hung C.F. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res. 2013, 73:119-127.
62. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
63. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., Rogers L.J., Gracia G.J., Jones S.A., Mangiameli D.P., Pelletier M.M., Gea-Banacloche J., Robinson M.R., Berman D.M., Filie A.C., Abati A., Rosenberg S.A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23:2346-2357.
64. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
65. Radvanyi L.G., Bernatchez C., Zhang M., Fox P.S., Miller P., Chacon J., Wu R., Lizee G., Mahoney S., Alvarado G., Glass M., Johnson V.E., McMannis J.D., Shpall E., Prieto V., Papadopoulos N., Kim K., Homsi J., Bedikian A., Hwu W.J., Patel S., Ross M.I., Lee J.E., Gershenwald J.E., Lucci A., Royal R., Cormier J.N., Davies M.A., Mansaray R., Fulbright O.J., Toth C., Ramachandran R., Wardell S., Gonzalez A., Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2012, 18:6758-6770.
66. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., Citrin D.E., Restifo N.P., Robbins P.F., Wunderlich J.R., Morton K.E., Laurencot C.M., Steinberg S.M., White D.E., Dudley M.E. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17:4550-4557.
67. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., Mu Z., Rasalan T., Adamow M., Ritter E., Sedrak C., Jungbluth A.A., Chua R., Yang A.S., Roman R.A., Rosner S., Benson B., Allison J.P., Lesokhin A.M., Gnjatic S., Wolchok J.D. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 2012, 366:925-931.
68. Brody J.D., Ai W.Z., Czerwinski D.K., Torchia J.A., Levy M., Advani R.H., Kim Y.H., Hoppe R.T., Knox S.J., Shin L.K., Wapnir I., Tibshirani R.J., Levy R. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J. Clin. Oncol. 2010, 28:4324-4332.
69. Kim Y.H., Gratzinger D., Harrison C., Brody J.D., Czerwinski D.K., Ai W.Z., Morales A., Abdulla F., Xing L., Navi D., Tibshirani R.J., Advani R.H., Lingala B., Shah S., Hoppe R.T., Levy R. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 2012, 119:355-363.
70. Bruchard M., Mignot G., Derangere V., Chalmin F., Chevriaux A., Vegran F., Boireau W., Simon B., Ryffel B., Connat J.L., Kanellopoulos J., Martin F., Rebe C., Apetoh L., Ghiringhelli F. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 2013, 19:57-64.
71. Tseng J., Citrin D.E., Waldman M., White D.E., Rosenberg S.A., Yang J.C. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer 2014, 120:1426-1432.
72. Klopp A.H., Spaeth E.L., Dembinski J.L., Woodward W.A., Munshi A., Meyn R.E., Cox J.D., Andreeff M., Marini F.C. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res. 2007, 67:11687-11695.
73. Galon J., Mlecnik B., Bindea G., Angell H.K., Berger A., Lagorce C., Lugli A., Zlobec I., Hartmann A., Bifulco C., Nagtegaal I.D., Palmqvist R., Masucci G.V., Botti G., Tatangelo F., Delrio P., Maio M., Laghi L., Grizzi F., Asslaber M., D'Arrigo C., Vidal-Vanaclocha F., Zavadova E., Chouchane L., Ohashi P.S., Hafezi-Bakhtiari S., Wouters B.G., Roehrl M., Nguyen L., Kawakami Y., Hazama S., Okuno K., Ogino S., Gibbs P., Waring P., Sato N., Torigoe T., Itoh K., Patel P.S., Shukla S.N., Wang Y., Kopetz S., Sinicrope F.A., Scripcariu V., Ascierto P.A., Marincola F.M., Fox B.A., Pages F. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J. Pathol. 2014, 232:199-209.
74. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405-409.
75. Kalos M., June C.H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013, 39:49-60.
76. Melero I., Rouzaut A., Motz G.T., Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discovery 2014, 4:522-526.
77. Kaneno R., Shurin G.V., Kaneno F.M., Naiditch H., Luo J., Shurin M.R. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell. Oncol. (Dordr.) 2011, 34:97-106.